SEC Form 4
AEON Biopharma, Inc. (AEON) insider trading
In the 12 months to Nov 21, 2026, 4 AEON insiders reported open-market purchases of $300.5K across 4 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $300.5K
- 4 filings
Who traded AEON, and when
- Purchase
AEON daily close from Nov 21, 2025 to Nov 20, 2026, between $0.11 and $1.36, last $0.12. 0 sale and 4 purchase filings by 4 insiders, marked at their filing dates. Timothy P. Lynch, 10% owner: bought $243.5K across 1 filing, first filed Aug 21, 2026, last Aug 21, 2026. Jennifer Sy, Chief Accounting Officer: bought $20.0K across 1 filing, first filed Nov 20, 2026, last Nov 20, 2026. Robert E. Bancroft, President and CEO: bought $19.6K across 1 filing, first filed Nov 20, 2026, last Nov 20, 2026. Alexander Blair Wilson, CLO, CSO and Corp Secretary: bought $17.5K across 1 filing, first filed Nov 20, 2026, last Nov 20, 2026.
Largest mark · tap a row for others
Timothy P. Lynch · 10% owner
Purchase $243,455
1,150,000 shares at $0.21 avg
Filed Aug 21, 2026 · traded Aug 19
Close on filing date $0.19
Timothy P. Lynch · 10% owner
10% owner
$243.5K boughtJennifer Sy · Chief Accounting Officer
Chief Accounting Officer
$20.0K boughtRobert E. Bancroft · President and CEO
President and CEO
$19.6K boughtAlexander Blair Wilson · CLO, CSO and Corp Secretary
CLO, CSO and Corp Secretary
$17.5K boughtOpen-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Timothy P. Lynch | 10% owner | — | $243.5K | 1 | — | |
| Jennifer Sy | Chief Accounting Officer | — | $20.0K | 1 | — | |
| Robert E. Bancroft | President and CEO | — | $19.6K | 1 | — | |
| Alexander Blair Wilson | CLO, CSO and Corp Secretary | — | $17.5K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Alexander Blair Wilson CLO, CSO and Corp Secretary | Purchase | 135,706 | $0.13 | $17.5K | 2,318,711 | |
traded | Jennifer Sy Chief Accounting Officer | Purchase | 153,846 | $0.13 | $20.0K | 1,655,022 | |
traded | Robert E. Bancroft President and CEO | Purchase | 152,333 | $0.13 | $19.6K | 3,329,436 | |
traded | Timothy P. Lynch 10% owner | Purchase | 1,150,000 | $0.21 | $243.5K | 6,500,000 |
GET /stocks/filings/vX/form-4?tickers=AEON&filing_date.gte=2025-11-21&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AEON"
],
"issuer_cik": "0001837607",
"owner_cik": "0001979602",
"accession_number": "0001979602-26-000007",
"form_type": "4",
"filing_date": "2026-11-20",
"period_of_report": "2026-11-20",
"issuer_name": "AEON Biopharma, Inc.",
"issuer_trading_symbol": "AEON",
"owner_name": "Wilson Alexander Blair",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CLO, CSO and Corp Secretary",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-20",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 135706,
"transaction_price_per_share": 0.1288,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 2318711,
"transaction_value": 17478.9328,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1235 to $0.1300 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"AEON"
],
"issuer_cik": "0001837607",
"owner_cik": "0002023998",
"accession_number": "0002023998-26-000007",
"form_type": "4",
"filing_date": "2026-11-20",
"period_of_report": "2026-11-19",
"issuer_name": "AEON Biopharma, Inc.",
"issuer_trading_symbol": "AEON",
"owner_name": "Sy Jennifer",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Accounting Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-19",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 153846,
"transaction_price_per_share": 0.1299,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 1655022,
"transaction_value": 19984.5954,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1290 to $0.1300 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 15 records
- Grants and awards13 records
- Other2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has AEON Biopharma, Inc.'s CEO sold stock?
No. Robert E. Bancroft (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is AEON’s insider data?
These are AEON Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AEON insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AEON every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.